Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors

Next Previous
X
Search
Trial Profile

An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary) ; Eftilagimod alpha (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant-mesothelioma; Oesophageal cancer; Peritoneal cancer; Rectal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms INSIGHT; INSIGHT Stratum D; INSIGHT-004; INSIGHT-005
  • Sponsors Merck KGaA

    • Most Recent Events

    • 29 Oct 2024 According to an Immutep Limited media release, The study is jointly funded with Merck KGaA, Darmstadt, Germany.
    • 31 Jul 2024 According to an Immutep Limited media release, Currently, 2 out of a target of 30 patients with metastatic urothelial cancer have been enrolled.
    • 04 Jun 2024 Study design were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top